Flash FinanceUS
Pre-market S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · ADMA Biologics (ADMA)

ADMA Biologics FY 2024 revenue rises 65% to $426.5 million; 2025 guidance raised

Mixed Impact 4 of 5 earnings Written later

ADMA Biologics reported full-year 2024 total revenue of $426.5 million, up 65% from 2023, and GAAP net income of $197.7 million, which includes an $84.3 million valuation allowance tax benefit. It raised its FY 2025 and 2026 revenue, Adjusted Net Income and Adjusted EBITDA guidance, but said it expects to file its Form 10-K late, on or before March 18, 2025, because KPMG has not yet completed its audit procedures.

Key points

  • FY 2024 revenue $426.5 million vs. $258.2 million in FY 2023; GAAP net income $197.7 million vs. a net loss of $28.2 million
  • FY 2024 Adjusted EBITDA $164.6 million and Adjusted Net Income $119.2 million, vs. $40.2 million and $0.7 million in FY 2023
  • FY 2025 total revenue guidance raised to more than $490 million; FY 2026 to more than $605 million
  • Company intends to file a Form 12b-25 and expects to file the Form 10-K on or before March 18, 2025; KPMG has not completed its audit procedures

The filing

CompanyADMA Biologics (ADMA)
Form8-K, current report
Filed with the SECMar 3, 2025, 4:06 PM ET
Accession number0001140361-25-006745

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 1:49 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on March 03, 2025.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.